Chairman of the Board
Members of the Cyxone board have extensive experience of taking projects from academic research stage to publicly traded development companies, fundraising as well as negotiating license and cooperation agreements.
Chairman of the Board
Born 1966. Chairman of the Board since 2015.
Dr Junno has previous management and board level experience from several European and US based companies in fields of electronics, biotech and IT. He has also co-founded several life science companies, for example WntResearch AB (publ), Galecto Biotech AB, Gabather AB (publ), Aptahem AB (publ) and Cyxone AB (publ). Dr Junno holds a Ph.D. in Semiconductor Physics and Technology and a M.Sc. in Physics from Lund University.
Bert Junno owns 400,000 shares in Cyxone. Junno further owns 1,788,732 shares in Cyxone through Fornio AB.
Born 1963. Board Member since 2016.
Theresa Comiskey Olsen, Attorney at Law (USA), is a Partner at Nova Law Firm in Oslo, Norway. Before joining Nova, Comiskey Olsen was a partner at Langseth Law Firm since January 2016 after starting her own practice with focus on legal transactions in the Life Sciences/Biotech field. Prior to starting her practice in 2008, she was General Counsel of Nycomed, which has since been acquired by Takeda. Comiskey Olsen continues to grow her practice at Nova with focus on legal transactions in the Life Sciences/Biotech field. She has her B.A. from University of Pennsylvania and her J.D. from University of Detroit Mercy School of Law.
Theresa Comiskey Olsen owns 100,000 shares in Cyxone
Born 1971. Board Member since 2015.
Saad Gilani is currently a Managing Director at Yorkville Advisors Global, a member of the company’s investment committee and a board member of Temple Therapeutics BV. As head of the Healthcare Group, he has led financing transactions in a variety of life science companies focusing on biotechnology, molecular diagnostics and medical equipment in the United States and Europe. Prior to joining Yorkville Advisors Global, Saad worked at Keyence Corporation for 11 years in engineering and marketing. He holds a Bachelor in Electrical Engineering from Rutgers College of Engineering and MBA from Rutgers University in New Jersey, where he specialized in finance.
Saad Gilani owns 132,500 shares in Cyxone
Born 1966. Board Member since 2015.
Mikael has 20 years’ experience in the Swedish start-up industry, during which he has been instrumental in the founding and development of Galecto Biotech, Cyxone, Gabather, Aptahem and nanotechnology companies, Portendo, NM Spintronics and Serstech as founder. Mikael’s contributions have generated investments of over €70M from business, private and public capital. Mikael has solid experience as a manager and board member in public companies, including responsibilities in company management, IPR, fundraising, negotiations and business development activities. In 2008-2014, Mikael was co-managing a Governmental investment fund focusing on life science and drug projects with strong IPR backbone and market potential. There, Mikael managed over 100 different assets which were capitalized though spin-outs, out-licensing and acquisitions. Accequa AB and Accequa GmbH are two investment vehicles for early stage life science assets where Mikael is a founder. Mikael holds a PhD in Inorganic Chemistry from Uppsala University and has Individual diplomas from programs in People Management, Coaching, Business and Project Development and Administration, Entrepreneurship, Marketing and Stock market ethics.
Mikael Lindstam owns 62,500 shares in Cyxone. Lindstam further owns 1,788,732 shares in Cyxone through Mikeoo Holding AB.
Born 1961. Board Member since 2021.
Alejandra Mørk is the CEO of KLIFO A/S, a Drug Development Consultancy company working for biotech and pharma companies in Europe and US, a company that she acquired in 2008 and have since then developed into a leading consulting company in the field in Scandinavia. Previously, she worked for Nycomed Pharma for 18 years, in various management positions in drug development and lifecycle management. She is also part of the EUCROF Paediatric Working Group.
Born 1955. Board Member since 2021.
Dr Peter Heinrich holds a PhD in biochemistry from Munich University and has during his career started a number of biotech companies in Europe. Dr Heinrich has over 20 years’ experience from various senior positions within research and development, licensing, new drug commercialization and business and corporate development as well as general management. He has also worked with start-up ventures, publicly held entities, strategic transactions, mergers and acquisitions. In total, Dr Heinrich’s transaction and deal volume exceeds 1 billion EUR.